StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Abbvie (ABBV) PT Raised to $180 at Goldman Sachs
February 5, 2024 5:58 AM
Goldman Sachs analyst Chris Shibutani raised the price target on Abbvie (NYSE: ABBV) to $180.00 (from $173.00) while maintaining a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Abbvie (ABBV) PT Raised to $167 at BofA Securities
February 5, 2024 5:42 AM
Abbvie (ABBV) PT Raised to $185 at Barclays
February 5, 2024 4:03 AM
Form 144 AbbVie Inc. Filed by: Siatis Perry C
February 2, 2024 5:51 PM
AbbVie (ABBV) tops Q4 earnings, revenue consensus estimate
February 2, 2024 8:37 AM
Form 8-K AbbVie Inc. For: Feb 02
February 2, 2024 7:51 AM
AbbVie raises 2027 sales forecast for new immunology drugs to $27 billion
February 2, 2024 7:39 AM
AbbVie (ABBV) Tops Q4 EPS by 2c, Beats on Revenue; Offers FY24 EPS Guidance
February 2, 2024 7:37 AM
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
February 2, 2024 7:36 AM
Payrolls, mega-cap tech earnings, Nvidia - what's moving markets
February 2, 2024 5:10 AM
Payrolls, mega-cap tech earnings, Nvidia - what's moving markets
February 2, 2024 5:10 AM
AbbVie (ABBV) call put ratio 1 call to 1.8 puts into quarter results and outlook
February 1, 2024 10:37 AM
AbbVie (ABBV) February weekly 165 straddle into quarter results
February 1, 2024 4:21 AM
